Pharmacological Profile of KP-496, a Novel Dual Antagonist for Cysteinyl Leukotriene Receptor (CysLT1R) and Thromboxane A2 Receptor (TP)

METHODS: 1) The in vitro profile of KP-496 was examined in various agonists induced contractions of guinea pig tracheae. 2) The effects of inhaled KP-496 on Leukotriene D4 (LTD4)- and U-46619 (a stable Thromboxane A2 mimetic)-induced bronchoconstriction were investigated in guinea pigs. 3) The effec...

Full description

Saved in:
Bibliographic Details
Published inJournal of allergy and clinical immunology Vol. 117; no. 2; p. S7
Main Authors Ishimura, M., Suda, M., Kataoka, S., Maeda, T., Hiyama, Y.
Format Journal Article
LanguageEnglish
Published St. Louis Elsevier Limited 01.02.2006
Subjects
Asthma
Studies
Online AccessGet full text

Cover

More Information
Summary:METHODS: 1) The in vitro profile of KP-496 was examined in various agonists induced contractions of guinea pig tracheae. 2) The effects of inhaled KP-496 on Leukotriene D4 (LTD4)- and U-46619 (a stable Thromboxane A2 mimetic)-induced bronchoconstriction were investigated in guinea pigs. 3) The effect of inhaled KP-496 on antigen-induced bronchoconstriction was compared with that of montelukast (a CysLT1R antagonist), seratrodast (a TP antagonist) and combined administration of montelukast and seratrodast in ovalbumin (OA) sensitized guinea pigs.
ISSN:0091-6749
1097-6825
DOI:10.1016/j.jaci.2005.12.030